primary studies - published RCT

Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis.

Code: PM11389575 **Year:** 2001 **Date:** 2001 **Author:** Ziebach R

Study design (if review, criteria of inclusion for studies)

Dual intervention cross-over trial over 4 days

Participants

17 participants (6 males), age range 7 - 33 years, 16 participants analysed

Interventions

Randomised to single dose nebulised placebo, salbutamol 5 mg, ipratropium 0.25 mg or combination

Outcome measures

Changes in spirometry (FVC, FEV1, FEF25-75, FEF50, TGV, Raw) measured at baseline and 30 minutes later

Main results

The mean forced expiratory volume in the first second improved significantly (adjusted P-value

Authors' conclusions

in CF patients bronchodilator therapy with sympathomimetic agents is usually sufficient. Only in cases with proven additional benefit from inhalation by anticholinergics should combination therapy be recommended.

http://dx.doi.org/10.1002/ppul.1071

See also

Pediatr Pulmonol. 2001 Jun;31(6):431-5.

Keywords

Adolescent; Adult; Albuterol; Biomarker; Bronchodilator Agents; Child; Combined Modality Therapy; Inhalation OR nebulised; Ipratropium; non pharmacological intervention - diagn; pharmacological_intervention; placebo; Salbutamol; Adrenergic beta-Agonists; Respiratory System Agents; Anticholinergic Agents;